menu search

Why is neurosense (nrsn) stock up 98% today?

NeuroSense (NASDAQ: NRSN ) stock is taking off on Thursday as investors react to data from a biomarker study concerning ...

January 19, 2023, 11:28 am

Why biogen's stock isn't soaring since its alzheimer's drug got approval

The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month....

January 19, 2023, 9:20 am

Anavex: drug treatments for early alzheimer's disease

Anavex 2-73/blarcamesine at high concentrations in early alzheimer's disease leads to improvements in c...

January 17, 2023, 5:10 pm

Biogen (biib) partner eisai seeks nod for lecanemab in japan

Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early alz...

January 16, 2023, 2:18 pm

Biovie inc: a catalyst-rich year ahead

BioVie's pipeline indications represent a combined addressable market size of more than $100 billion with high unmet medical needs. Phase 2 trials hav...

January 16, 2023, 12:04 am

Voyager: recent neurocrine deal signals more upside

In trying to deliver breakthrough, Voyager Therapeutics is able to ink multiple robust deals with reputable companies. The company is trying to tackle...

January 14, 2023, 4:19 am

Prothena (prta) stock gains 88.5% in 6 months: what lies ahead?

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising alzheimer...

January 13, 2023, 3:48 pm

Anavex: despite positive spin, no clarity on anomalies

Anavex Life Sciences Corp. presented solid-looking alzheimer's data last month. Critics found a number ...

January 12, 2023, 10:49 am

Biogen's (biib) partner eisai files maa for lecanemab in europe

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early ...

January 11, 2023, 11:17 am

Cms limiting coverage of alzheimer's drug not a 'fixed' policy, says fda's robert califf

CNBC's Meg Tirrell and Dr. Robert Califf, FDA commissioner, joins 'Power Lunch' to discuss Biogen's alzheimer<...

January 10, 2023, 3:32 pm

Alnylam pharmaceuticals starts 2023 with in-line revenue and a full slate of clinical read-outs

Alnylam's fourth quarter product revenue was more or less as expected, with a faster/better-than-expected pace of switching between Onpattro and Amvut...

January 10, 2023, 12:59 pm

Should you buy biogen stock after its latest alzheimer's disease drug approval?

There's more to the story with Biogen after receiving good news for Leqembi....

January 10, 2023, 5:55 am

Cerevel therapeutics to present at 41st annual j.p. morgan healthcare conference and provide pipeline update

Initiated Phase 1 healthy volunteer trial to support development of emraclidine in alzheimer's disease ...

January 9, 2023, 6:30 am

Eisai files for full fda approval for alzheimer's drug leqembi

Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its...

January 6, 2023, 11:42 pm

The fda approved the alzheimer’s drug leqembi from eisai and biogen

The FDA approved the alzheimer’s drug Leqembi from Eisai and Biogen Read Full Story The post The FDA ...

January 6, 2023, 7:25 pm

Fda approves biogen, eisai alzheimer's drug

An alzheimer's drug from Biogen and Eisai has received accelerated approval from the Food and Drug Admi...

January 6, 2023, 7:10 pm

Cnbc exclusive: eisai u.s. ceo on alzheimer's drug approval

CNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's alzheimer's drug receiving app...

January 6, 2023, 6:05 pm

Fda approves biogen-eisai alzheimer's drug, china in talks to make pfizer paxlovid generic

Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative al...

January 6, 2023, 5:33 pm

Fda approves biogen's alzheimer's drug

CNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an alzheimer's treatmen...

January 6, 2023, 2:59 pm

Fda approves treatment for people with mild forms of alzheimer's

The Food and Drug Administration on Friday granted an accelerated approval to Eisai and Biogen's alzheimer...

January 6, 2023, 2:41 pm


Search within

Pages Search Results: